Axsome Therapeutics (AXSM) Change in Accured Expenses (2015 - 2026)

Axsome Therapeutics has disclosed Change in Accured Expenses across 12 years of filings, most recently posting $17.2 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $17.2 million, up 2006.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $100.2 million (up 53.38% YoY), and the FY2025 annual result was $83.7 million, up 49.37% from the prior year.
• Change in Accured Expenses came in at $17.2 million for Q1 2026 at Axsome Therapeutics, up from $7.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $54.2 million in Q3 2025 to a low of -$8.4 million in Q1 2024.
• The 5-year median for Change in Accured Expenses is $11.4 million (2023), against an average of $14.0 million.
• Across the five-year window, Change in Accured Expenses surged 8238.14% in 2022 and slumped 217.81% in 2024, its largest moves.
• Axsome Therapeutics' Change in Accured Expenses stood at $13.2 million in 2022, then declined by 13.91% to $11.4 million in 2023, then jumped by 125.95% to $25.7 million in 2024, then plunged by 72.05% to $7.2 million in 2025, then jumped by 140.16% to $17.2 million in 2026.
• The last three Change in Accured Expenses figures came in at $17.2 million (Q1 2026), $7.2 million (Q4 2025), and $54.2 million (Q3 2025), per Business Quant data.